- $61.25m
- $3.18m
- $27.29m
- 52
- 54
- 36
- 45
Annual balance sheet for Zomedica, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 62 | 195 | 115 | 90.5 | 71.4 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.146 | 0.765 | 1.86 | 2.2 | 3.07 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 62.9 | 200 | 124 | 99.9 | 81.8 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.9 | 2.53 | 9.17 | 25.3 | 26.2 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 66.1 | 280 | 280 | 253 | 207 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.03 | 4.34 | 7.81 | 9.03 | 9.33 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 3.12 | 9.51 | 12.2 | 13.2 | 11.7 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 63 | 271 | 267 | 240 | 196 |
| Total Liabilities & Shareholders' Equity | 66.1 | 280 | 280 | 253 | 207 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |